novartis entresto - Search News

News

Novartis Lifts Profit Outlook

The Wall Street Journal on MSN · 1d

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in second-quarter sales and earnings.

Invezz on MSN · 1d

Novartis lifts full-year profit forecast, announces $10 billion share buyback

Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter.

CNBC on MSN · 1d

Novartis raises outlook on strong second-quarter sales

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.

2don MSN

Novartis cannot block generic version of Entresto, judge rules

A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

1d

Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

18h

Novartis AG (NVS) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic Initiatives ...

Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...

7don MSN

Novartis loses bid to block US Entresto generic through 2026

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Drug Store News1d

U.S. federal judge rejects Novartis’ efforts to block MSN's generic Entresto

Novartis could soon face generic competition for Entresto after judge's ruling.

The Pharma Letter10h

US Entresto patent ruling is a mixed bag for Indian pharma

In what is not exactly a win-win situation for the Indian generic firms, a recent federal court ruling in Delaware, USA, has ...

1d

Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...

Fierce Pharma1d

Novartis’ Pluvicto finally picks up speed, delivers another trial win in early prostate cancer

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

NDTV Profit on MSN4d

Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results